Maven Securities’s Adaptive Biotechnologies ADPT Stock Holding History

Maven Securities’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-430,616	Closed	-$25.6M	–	1157
2020 Q4	$25.6M	Buy	430,616 +55,616	+15%	+$2.87M	2.53%	2
2020 Q3	$18M	Buy	+375,000	New	+$15.8M	1.49%	10
2020 Q1	–	Sell	-78,223	Closed	-$2.34M	–	303
2019 Q4	$2.34M	Buy	+78,223	New	+$2.25M	0.21%	90
2019 Q3	–	Sell	-52,500	Closed	-$2.51M	–	204
2019 Q2	$2.51M	Buy	+52,500	New	+$2.33M	1.67%	25

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Maven Securities's ADPT Position: Q1 2021 in Review

Maven Securities sold out of Adaptive Biotechnologies (ADPT) in Q1 2021, closing a stake of 430,616 shares — an estimated $25.6M sold.

Maven Securities first reported a position in ADPT in Q2 2019 and held it in 4 quarters. The position peaked at $25.6M in Q4 2020. 248 funds tracked by Wall St. Rank hold ADPT as of Q1 2021.

Maven Securities reported no remaining Adaptive Biotechnologies position as of Q1 2021 after selling out during the quarter.
Maven Securities sold 430,616 Adaptive Biotechnologies shares in Q1 2021, an estimated $25.6M.
Maven Securities first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 4 quarters.
Maven Securities's Adaptive Biotechnologies position peaked at $25.6M in Q4 2020.
248 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.